Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
877.79
-31.53 (-3.47%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
99
100
Next >
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
April 12, 2024
A powerfully bullish new analyst take on the company helped it rally on the market.
Via
The Motley Fool
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
April 12, 2024
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled...
Via
Benzinga
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy
April 12, 2024
U.S. District Judge Roy Altman's ruling prohibits Eli Lilly from using state law to halt RXCompoundStore.com's marketing of its tirzepatide version. The court asserts federal law enforcement authority,...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
April 12, 2024
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough...
Via
Benzinga
Exposures
Product Safety
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
April 12, 2024
Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end?
Via
Investor's Business Daily
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
April 09, 2024
Via
Benzinga
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
April 12, 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
Via
InvestorPlace
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
April 12, 2024
For investors looking for a way to play weight-loss stocks in this current backdrop, here are three top options to consider right now.
Via
InvestorPlace
Why Roche Holdings Stock Popped Today
April 11, 2024
Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate.
Via
The Motley Fool
Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for April 2024
April 11, 2024
Investors wanting to broaden and deepen their portfolio should reach for these healthcare names, each of which is a favorite among analysts.
Via
InvestorPlace
Trillion-Dollar Trajectories: 3 Billion-Dollar Stocks With the Potential to Hit the Next Milestone
April 11, 2024
Looking for your next picks? These top-performing market leaders have the potential to be the next trillion-dollar companies.
Via
InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
April 10, 2024
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments
Via
InvestorPlace
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
April 10, 2024
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections...
Via
Benzinga
The Next "Magnificent Seven"?
April 10, 2024
Here is a look at the stocks that might comprise the next "Magnificent Seven."
Via
The Motley Fool
Jim Cramer Stands By Nvidia And Eli Lilly Despite Market Dips, Says 'Terrific Time To Take Some Profits'
April 09, 2024
Cramer observed that despite the losses, these stocks have a lot to offer. He noted that these stocks have surged so much that they've become susceptible to market volatility.
Via
Benzinga
MarketMasterAI’s Top 500 Stocks: April 2024
April 09, 2024
My MarketMasterAI system has ranked the top 500 stocks to buy in April and the winners look really different than in January. Here's why.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
April 09, 2024
Via
Benzinga
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
April 09, 2024
These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term.
Via
InvestorPlace
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
April 09, 2024
These companies are close to launching new products that could supercharge revenue.
Via
The Motley Fool
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 09, 2024
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market
Via
MarketBeat
Exposures
Product Safety
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
April 09, 2024
These stocks, a bargain today, are players to hold on to for the long term.
Via
The Motley Fool
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
April 08, 2024
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend
Via
MarketBeat
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
April 08, 2024
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a...
Via
Benzinga
2 Growth Stocks to Buy Hand Over Fist in April
April 08, 2024
These healthcare companies' target markets substantially overlap.
Via
The Motley Fool
This 1 Number May Ensure Eli Lilly's Dominance in the Weight Loss Drug Market
April 08, 2024
Lilly's stock has climbed in the triple digits over the past 12 months.
Via
The Motley Fool
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
April 08, 2024
Shares of the clinical-stage biotech have skyrocketed on recent good news.
Via
The Motley Fool
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
April 07, 2024
New findings could lead to more growth from their prized medicines.
Via
The Motley Fool
Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock
April 06, 2024
Things are going exactly as planned for the biotech giant.
Via
The Motley Fool
Traders Rethink Interest Rate Cuts, Labor Market Heats Up, Oil Prices Quietly Reach 6-Month High: This Week In The Markets
April 05, 2024
U.S. economy resilient, manufacturing and labor market strong. Fed officials temper rate cut expectations. Apple shifts focus to home robotics.
Via
Benzinga
Topics
Economy
Exposures
Economy
Interest Rates
Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds
April 05, 2024
Corporate bonds offer yield opportunities and diversification away from equity investments. Investment-grade bonds are safer but lower yield, while high-yield bonds offer higher returns but from...
Via
Benzinga
Topics
Bonds
Exposures
Debt Markets
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.